Riverview Trust Coと投資家は、好調な収益と「中程度の買い」の評価にもかかわらず、AbbVieの株式を調整します。 Riverview Trust Co and investors adjust stakes in AbbVie, despite strong earnings and a "Moderate Buy" rating.

Riverview Trust Co.とその他の機関投資家は、AbbVie Inc.の株式を調整し、一部の株式を売却し、他の投資家は保有を増やしました。 Riverview Trust Co and other institutional investors have adjusted their stakes in AbbVie Inc., with some selling off shares and others increasing their holdings. AbbVieの株式は330億82億円で評価され,同社は強い収益を報告し,同社は2.46 EPSと見積もっている. AbbVie's stock is valued at $330.82 billion, and the company reported strong earnings, beating estimates with $2.46 EPS. 株式は212.19の目標価格を掲げる"モデレート・バイヤー"の格付けを有する. The stock has a "Moderate Buy" rating with a target price of $212.19. EVPジェフリー・ライアン・スチュワートも8万832株を売却し,所有権を52.50%削減した. EVP Jeffrey Ryan Stewart also sold 58,832 shares, reducing his ownership by 52.50%.